Cellectis (NASDAQ:CLLS) Announces Earnings Results

Cellectis (NASDAQ:CLLS) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.08, Zacks reports. Cellectis had a negative net margin of 84.92% and a negative return on equity of 69.38%.

Cellectis Price Performance

Shares of Cellectis stock traded up $0.13 during trading on Monday, reaching $3.98. The company’s stock had a trading volume of 29,003 shares, compared to its average volume of 41,561. The stock has a 50-day moving average price of $3.68 and a two-hundred day moving average price of $4.00. The company has a current ratio of 1.62, a quick ratio of 1.62 and a debt-to-equity ratio of 0.98. Cellectis has a one year low of $1.33 and a one year high of $5.48. The stock has a market capitalization of $399.35 million, a P/E ratio of -5.94 and a beta of 2.94.

Analyst Ratings Changes

CLLS has been the subject of a number of analyst reports. Jefferies Financial Group initiated coverage on Cellectis in a report on Tuesday, February 17th. They set a “buy” rating and a $7.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a report on Monday, April 20th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $8.00 price objective on shares of Cellectis in a report on Tuesday, April 14th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $6.75.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Global Retirement Partners LLC bought a new position in shares of Cellectis in the fourth quarter valued at about $34,000. Virtu Financial LLC acquired a new stake in Cellectis in the third quarter worth about $72,000. Acadian Asset Management LLC increased its position in Cellectis by 132.9% in the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 26,461 shares during the period. Millennium Management LLC increased its position in Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 22,080 shares during the period. Finally, Marshall Wace LLP increased its position in Cellectis by 1,610.3% in the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock worth $864,000 after purchasing an additional 168,038 shares during the period. 63.90% of the stock is owned by institutional investors.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.